Division of Respiratory Surgery, Nihon University School of Medicine, Tokyo, Japan.
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Eur J Cardiothorac Surg. 2024 Mar 29;65(4). doi: 10.1093/ejcts/ezae158.
To validate or refute the hypothesis that non-small-cell lung cancers (NSCLC) with ground-glass areas (GGA+) within the tumour on high-resolution computed tomography are associated with a more favourable prognosis than those without GGA (GGA-).
We analysed data from a multicentre observational cohort study in Japan including 5005 patients with completely resected pathological stage I NSCLC, who were excluded from the Japan Clinical Oncology Group (JCOG) 0707 trial on oral adjuvant treatment during the enrolment period. The patients' medical and pathological records were assessed retrospectively by physicians and re-staged according to the 8th tumour, node, metastasis edition.
Of the 5005 patients, 2388 (48%) were ineligible for the JCOG0707 trial and 2617 (52%) were eligible but were not enrolled. A total of 958 patients (19.1%) died. Patients with GGA+ NSCLC and pathological invasion ≤3 cm showed significantly better overall survival than others. In patients with tumours with an invasive portion ≤4 cm, GGA+ was associated with better survival. The prognoses of patients with GGA+ T2a and GGA- T1c tumours were similar (5-year overall survival: 84.6% vs 83.1%, respectively). The survival with T2b or more tumours appeared unaffected by GGA, and GGA was not prognostic in these larger tumours.
Patients with GGA+ NSCLC on high-resolution computed tomography and ≤4 cm invasion size may have a better prognosis than patients with solid GGA- tumours of the same T-stage. However, the presence or absence of radiological GGA has little impact on the prognosis of patients with NSCLC with greater (>4 cm) pathological invasion.
验证或反驳非小细胞肺癌(NSCLC)肿瘤内存在磨玻璃影(GGA+)与无 GGA(GGA-)的肿瘤相比具有更有利预后的假设。
我们分析了来自日本多中心观察队列研究的数据,该研究纳入了 5005 例完全切除的病理 I 期 NSCLC 患者,这些患者在入组期间被排除在日本临床肿瘤学组(JCOG)0707 口服辅助治疗试验之外。通过医生对患者的医疗和病理记录进行回顾性评估,并根据第 8 版肿瘤、淋巴结、转移分期重新分期。
在 5005 例患者中,有 2388 例(48%)不符合 JCOG0707 试验条件,2617 例(52%)符合条件但未入组。共有 958 例(19.1%)死亡。GGA+ NSCLC 且病理侵袭≤3cm 的患者总生存明显优于其他患者。在侵袭性部分≤4cm 的肿瘤患者中,GGA+与更好的生存相关。GGA+ T2a 和 GGA- T1c 肿瘤患者的预后相似(5 年总生存率:分别为 84.6%和 83.1%)。侵袭性更大(T2b 或更严重)肿瘤的生存似乎不受 GGA 影响,GGA 在这些更大的肿瘤中对预后无影响。
高分辨率计算机断层扫描上存在 GGA+ NSCLC 且侵袭性≤4cm 的患者可能比具有相同 T 分期的实性 GGA-肿瘤患者具有更好的预后。然而,影像学上 GGA 的存在与否对具有更大(>4cm)病理侵袭的 NSCLC 患者的预后影响不大。